CHAPEL HILL, N.C. (May 16, 2018)—The U.S. Food and Drug Administration (FDA) has given Bleep clearance to market its Bleep DreamPort, a light and headgear-free CPAP interface.

Bleep’s DreamPort aims to solve the major current problems with many masks in the industry: comfort, bothersome headgear, leaks, weight and size restrictions.

The DreamPort was developed by founder and CEO Stuart Heatherington Registered Polysomnographic Technologist (RPSGT) and a 20-year CPAP patient, this project is the culmination of an eight-year-long process to “Make the Mask a Thing of the Past.”

Visit for more information.